BlackRock, Inc. 13D and 13G filings for Ligand Pharmaceuticals Incorporated:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-02-05 1:23 pm Sale |
2024-12-31 | 13G | Ligand Pharmaceuticals Incorporated LGND |
BlackRock Inc. BLK |
2,945,939 15.600% |
-16,155 (-0.55%) |
Filing |
| 2024-01-22 2:03 pm Purchase |
2023-12-31 | 13G | Ligand Pharmaceuticals Incorporated LGND |
BlackRock Inc. BLK |
2,962,094 17.000% |
172,615 (+6.19%) |
Filing |
| 2023-01-26 08:52 am Unchanged |
2022-12-31 | 13G | Ligand Pharmaceuticals Incorporated LGND |
BlackRock Inc. BLK |
2,789,479 16.500% |
0 (Unchanged) |
Filing |
| 2023-01-20 5:17 pm Sale |
2022-12-31 | 13G | Ligand Pharmaceuticals Incorporated LGND |
BlackRock Inc. BLK |
2,789,479 16.500% |
-1,607,242 (-36.56%) |
Filing |
| 2022-01-27 11:00 am Unchanged |
2021-12-31 | 13G | Ligand Pharmaceuticals Incorporated LGND |
BlackRock Inc. BLK |
4,396,721 16.400% |
0 (Unchanged) |
Filing |
| 2022-01-25 3:03 pm Purchase |
2021-12-31 | 13G | Ligand Pharmaceuticals Incorporated LGND |
BlackRock Inc. BLK |
4,396,721 16.400% |
1,245,230 (+39.51%) |
Filing |
| 2021-01-26 6:52 pm Sale |
2020-12-31 | 13G | Ligand Pharmaceuticals Incorporated LGND |
BlackRock Inc. BLK |
3,151,492 12.200% |
-671,917 (-17.57%) |
Filing |